Budesonide/azelastine solution - Sedor Pharmaceuticals

Drug Profile

Budesonide/azelastine solution - Sedor Pharmaceuticals

Alternative Names: CDX-313; LGD-313

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Immunosuppressants; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 08 Dec 2015 Captisol-enabled™ budesonide/azelastine licensed to RODES Pharmaceuticals in USA
  • 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)
  • 26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top